• LAST PRICE
    54.4100
  • TODAY'S CHANGE (%)
    Trending Down-1.3800 (-2.4736%)
  • Bid / Lots
    52.7500/ 1
  • Ask / Lots
    60.0000/ 5
  • Open / Previous Close
    54.9600 / 55.7900
  • Day Range
    Low 53.7250
    High 56.0900
  • 52 Week Range
    Low 30.7400
    High 75.1000
  • Volume
    352,296
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 55.79
TimeVolumeACLX
09:32 ET244454.93
09:34 ET69055.77
09:36 ET10056.09
09:38 ET45055.68
09:39 ET10056.02
09:41 ET31756.045
09:45 ET10055.89
09:50 ET10055.98
09:52 ET20055.96
09:54 ET615255.77
09:56 ET320055.58
09:57 ET433055.58
09:59 ET300155.645
10:01 ET172055.34
10:03 ET54855.23
10:08 ET10055.055
10:10 ET76255.27
10:12 ET146755.02
10:14 ET37954.99
10:15 ET40755
10:19 ET25055.045
10:21 ET10054.87
10:24 ET10054.975
10:26 ET43754.9749
10:28 ET150054.98
10:30 ET40055.05
10:32 ET20054.9
10:33 ET40054.93
10:35 ET302554.77
10:37 ET10054.76
10:39 ET70054.92
10:42 ET30054.8
10:44 ET10054.81
10:46 ET49654.895
10:48 ET63055.03
10:50 ET10055.01
10:53 ET228755.395
10:57 ET272155.69
11:00 ET40055.8
11:02 ET100055.81
11:04 ET43156.01
11:06 ET370055.58
11:08 ET10055.445
11:09 ET70055.22
11:13 ET40055.135
11:15 ET60055.045
11:18 ET110055.1
11:29 ET20055.28
11:31 ET10055.195
11:36 ET71255.215
11:42 ET40054.86
11:44 ET33154.86
11:47 ET20054.8
11:51 ET10054.83
11:54 ET20054.76
11:56 ET30054.83
11:58 ET12054.78
12:00 ET10054.76
12:02 ET170054.91
12:05 ET10054.84
12:09 ET75954.96
12:18 ET90054.96
12:20 ET20054.99
12:25 ET10054.9734
12:27 ET60954.9
12:34 ET29154.88
12:38 ET30054.87
12:41 ET60054.92
12:43 ET80054.965
12:50 ET10054.985
12:54 ET89254.975
12:56 ET10054.88
01:06 ET40054.9
01:08 ET10054.84
01:12 ET100054.93
01:21 ET20054.875
01:28 ET10054.69
01:30 ET10054.67
01:33 ET10054.5
01:37 ET10054.51
01:42 ET117654.5
01:44 ET30054.5
01:46 ET277654.69
01:55 ET112754.53
01:57 ET30054.485
02:00 ET20054.26
02:02 ET100054.185
02:08 ET15454.1056
02:09 ET90054.185
02:11 ET20054.1
02:13 ET10054.1
02:18 ET20054.18
02:20 ET20054.11
02:22 ET80053.91
02:24 ET10053.89
02:26 ET124253.9
02:27 ET330054.105
02:31 ET17953.95
02:36 ET28054.11
02:38 ET40054.04
02:40 ET20054.115
02:42 ET50354.03
02:44 ET10054.005
02:45 ET20054.015
02:47 ET50053.96
02:49 ET30053.91
02:51 ET361253.895
02:54 ET184953.825
02:56 ET183053.935
03:00 ET50053.94
03:02 ET331854.0825
03:07 ET100454.23
03:09 ET30054.245
03:12 ET72854.22
03:14 ET100054.015
03:18 ET10053.85
03:20 ET185253.805
03:21 ET200553.91
03:23 ET241354.105
03:27 ET20554.23
03:30 ET40054.22
03:32 ET30054.14
03:38 ET369254.24
03:39 ET60054.28
03:41 ET30054.35
03:43 ET50654.265
03:45 ET30054.27
03:48 ET90054.21
03:50 ET217154.18
03:52 ET290054.115
03:54 ET225154.09
03:56 ET1004953.97
03:57 ET1307954.25
03:59 ET2457054.41
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesACLX
Arcellx Inc
2.9B
-52.4x
---
United StatesRYTM
Rhythm Pharmaceuticals Inc
2.6B
-9.3x
---
United StatesIDYA
IDEAYA Biosciences Inc
2.9B
-19.1x
---
United StatesSWTX
SpringWorks Therapeutics Inc
2.9B
-7.5x
---
United StatesGERN
Geron Corp
2.9B
-14.1x
---
United StatesBHVN
Biohaven Ltd
3.0B
-5.0x
---
As of 2024-06-15

Company Information

Arcellx, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The Company’s lead program is a BCMA-targeting ddCAR product candidate called CART-ddBCMA, which is being evaluated in its pivotal Phase II iMMagine-1 trial in patients with relapsed or refractory multiple myeloma (rrMM). The Company is also developing two clinical-stage ARC-SparX programs in Phase I trials; ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Outside of multiple myeloma (MM), the Company advances its wholly owned portfolio of clinical-stage, ACLX-002, and preclinical pipeline programs incorporating its D-Domain technology. D-Domain, is designed to overcome the limitations of traditional Chimeric Antigen Receptor T-cells (CAR-Ts).

Contact Information

Headquarters
800 Bridge ParkwayREDWOOD CITY, CA, United States 94065
Phone
240-327-0603
Fax
302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer
Rami Elghandour
Chief Financial Officer
Michelle Gilson
Chief Medical Officer
Christopher Heery
Independent Director
Ali Behbahani
Independent Director
Jill Carroll

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$2.9B
Revenue (TTM)
$131.7M
Shares Outstanding
53.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.04
Book Value
$9.28
P/E Ratio
-52.4x
Price/Sales (TTM)
22.1
Price/Cash Flow (TTM)
---
Operating Margin
-57.14%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.